Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05847049
Other study ID # N-20-2023
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 28, 2023
Est. completion date April 6, 2023

Study information

Verified date April 2023
Source Dar El Oyoun Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR


Description:

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021 After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac. Investigators collected and recorded the following data: - Age - Gender - Systemic hypertension (present or not) - Smoking (Yes / No) - Best corrected visual acuity (BCVA) (baseline, final) - Central macular thickness (CMT) (baseline, final) - Serous detachment Height (SDH) (baseline, final) - Duration of Follow-up ( in months)


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date April 6, 2023
Est. primary completion date March 25, 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years to 60 Years
Eligibility Inclusion Criteria: - CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac. Exclusion Criteria: - • CSCR treated by other modalities - CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Locations

Country Name City State
Egypt Kasr alainy faculty of medicine Cairo

Sponsors (1)

Lead Sponsor Collaborator
Dar El Oyoun Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in central macular thickness (CMT ) in microns reduction in CMT after therapy (baseline, 6 months)
Primary Change in serous detachment height (SDH) in microns reduction in SDH after therapy (baseline, 6 months)
Secondary Change in BCVA number of lines of improvement in BCVA after therapy (baseline, 6 months)
Secondary Duration of Follow-up ( in months) Duration of Follow-up ( in months) (baseline, 6 months)
Secondary Complications (Eplerenone, Aflibercept, and nepafenac) present or absent (baseline, 6 months)
See also
  Status Clinical Trial Phase
Completed NCT03497000 - Effects of OCTA-guided PDT in Acute CSC N/A
Recruiting NCT03692169 - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting NCT02215330 - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Phase 2/Phase 3
Completed NCT01990677 - Eplerenone for the Treatment of Central Serous Chorioretinopathy N/A
Completed NCT01971190 - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT01710332 - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT00403884 - Selective RPE Laser Treatment (SRT) for Various Macular Diseases N/A
Recruiting NCT05570591 - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy N/A
Recruiting NCT05589974 - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed NCT05104138 - Eplerenone Versus PDT: Comparative Study by OCTA
Completed NCT01880788 - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD N/A
Terminated NCT01982383 - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy N/A
Completed NCT01327170 - Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy N/A
Completed NCT01019668 - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy N/A
Recruiting NCT06346405 - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01822561 - Eplerenone for Central Serous Chorioretinopathy Phase 2
Completed NCT00802906 - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) N/A
Withdrawn NCT05679180 - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE N/A
Completed NCT05686421 - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations N/A